Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Iovance Biotherapeutics Inc maintains a gross margin of 29.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -133.06%, while the net margin is -135.28%. These profitability ratios, combined with a Return on Equity (ROE) of -53.89%, provide a clear picture of how effectively IOVA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IOVA competes directly with industry leaders such as VIR and ZBIO. With a market capitalization of $1.02B, it holds a significant position in the sector. When comparing efficiency, IOVA's gross margin of 29.61% stands against VIR's 104.58% and ZBIO's 100.00%. Such benchmarking helps identify whether Iovance Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.
